Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.74 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.57 |
| ▸ | TPH1 | P17752 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901480 | 0.91 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1DHFR | |
| SCHEMBL901947 | 0.90 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1DHFRHDAC8 | |
| Hydrochloric Acid SCHEMBL902231 | 0.90 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1DHFRHDAC8 | |
| SCHEMBL901950 | 0.90 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1 | |
| SCHEMBL904228 | 0.86 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1MGLL | |
| SCHEMBL902029 | 0.85 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1DHFRLRRK2 | |
| SCHEMBL903978 | 0.85 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1DHFRLRRK2 | |
| Hydrochloric Acid SCHEMBL15091299 | 0.84 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1DHFRLRRK2 | |
| SCHEMBL15091322 | 0.84 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1DHFR | |
| Hydrochloric Acid SCHEMBL15091321 | 0.84 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1DHFRLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | claimed |
| EP-2621919-A1 | PHENYLQUINAZOLINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | claimed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | claimed |
| WO-2012041435-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | claimed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2621919-A1 | PHENYLQUINAZOLINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| WO-2012041435-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041435-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885TPH1 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.